Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick K Reville

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Cancer Immunology Research|May 10, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal HyperexpansionPoonam N Desai, Bofei Wang, Andre Fonseca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Nature Communications|February 28, 2024
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategiesBofei Wang, Patrick K Reville, Mhd Yousuf Yassouf, et al.
Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Leukemia|December 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Cancer Immunology Research|May 10, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal HyperexpansionPoonam N Desai, Bofei Wang, Andre Fonseca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Nature Communications|February 28, 2024
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategiesBofei Wang, Patrick K Reville, Mhd Yousuf Yassouf, et al.
Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Leukemia|December 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Pageof 4